Independent experts voted 10-3 despite regulators’ concern about the design of the company’s pivotal cancer trial. https://t.co/l5iT3dRdMG ...

The weight-loss drug boom is beginning to show signs of a slowdown as employers and insurers pull back on coverage, signaling the market could be entering a more restrained phase after years of breakneck expansion https://t.co/qx74Utphq0 ...

Bristol Myers boosted its sales and profit outlook for 2026 after second-quarter demand for most of the drugmaker’s portfolio beat Wall Street’s expectations, led by newer medicines for heart conditions and cancer. https://t.co/R9azm5DP8J ...

Bristol Myers Squibb raised its outlook for the year after notching higher profit and revenue in the latest quarter, boosted by its portfolio of newer treatments. https://t.co/40umEFpbpY ...

Dr. Reddy’s expects its generic anti-obesity drug to shore up growth in the six months through March https://t.co/BbASXufc2g ...

Industry Trends - Pharmaceutical companies adopt artificial intelligence to accelerate drug development processes [1] Corporate Strategy - GlaxoSmithKline (GSK) establishes new strategic partnerships utilizing artificial intelligence technologies [1]

Sanofi reported better-than-expected profit growth and nudged its guidance higher, helped by surging demand for its top-selling skin and asthma medicine Dupixent https://t.co/hRInlbji4j ...

PAUL: I'M PAUL ALLEN. THIS IS INSIGHT WHERE WE DIVE DEEPER INTO THE STORIES THAT MATTER. >> WE UNDERSTAND THAT THE FIVE PLUS YEARS OF INFLATION ABOVE TARGET CANNOT BE CURED IN NINE WEEKS.OR BUT A SINGLE MONTH OF MODEST PRICE DECREASES. THIS FED WILL NOT WAIVER. -- WAVER.PAUL: A HAWKISH FED LEADS RATES UNCHANGED FOR A SEVENTH STRAIGHT MONTH BUT LONG BOND YIELDS JUMP AS INVESTORS QUESTION FED CHAIR WARSH'S INFLATION FIGHTING RESOLVE. SOUTH KOREAN STOCKS BOUNCE BACK AFTER SAMSUNG EARNINGS. OFFICIALS PLEDGING N ...